Yale Bulletin and Calendar

January 11, 2008|Volume 36, Number 14

Antibody may delay development of diabetes

An antibody used to treat certain cancers and rheumatoid arthritis appears to greatly delay type 1 diabetes in mice, Yale School of Medicine researchers report in the Journal of Clinical Investigation.

“Even better, the beneficial effects of the antibody continue to be observed long after the antibody is no longer administered,” the researchers say.

The antibody, rituximab (anti-CD20), depletes B cells. Experimental evidence in mutant mice indicates that B cells play a role in autoimmune diseases by interacting with T cells of the immune system. It is T cells that destroy insulin-producing cells directly in the pancreas, leading to type 1 diabetes.

“Our paper shows, for the first time, that after successful B cell depletion, regulatory cells emerge that can continue to suppress the inflammatory and autoimmune response even after the B cells return,” said Li Wen, senior research scientist in the division of endocrinology. “Even more strikingly, we found that these regulatory cells include both B and T cells.”

To determine if B cell depletion would work as a therapy for type 1 diabetes, Wen and her Yale colleague, Dr. Mark Shlomchik, professor of laboratory medicine and immunobiology, developed a mouse model. They engineered mice that were predisposed to diabetes and had the human version of CD20, the molecule rituximab targets, on the surface of their B cells.

The researchers tested a mouse version of the drug to deplete B cells in mice either before diabetes onset, or within days of diagnosis with diabetes. The drug treatment significantly delayed diabetes onset in pre-diabetic mice. This translated to a 10- to 15-week delay in developing diabetes compared to mice given a “sham” treatment. The equivalent period for humans would be approximately 10 to 15 years. Of the 14 mice that already had diabetes, five stopped needing insulin for two to five months while all the sham-treated mice remained diabetic.

?“These studies suggest that B cells can have dual roles in diabetes and possibly other autoimmune diseases. The B cells might promote disease initially, but after being reconstituted following initial depletion with rituximab, they actually block further disease,” Shlomchik says. “This means that multiple rounds of medication to deplete the B cells might not be necessary or even advisable.”

— By Jacqueline Weaver

T H I SW E E K ' SS T O R I E S

University is increasing payout from endowment

Stern named to third term as dean of School of Architecture

Findings set stage for prevention of epilepsy

Antibody may delay development of diabetes

Scientists determine intricate process used in assembly . . .

Mutant gene identified as ‘villain’ in hardening of the arteries

Researchers find gene that protects newborns . . .

Yale Rep stages the world premiere of ‘The Evildoers’

Exhibit reveals the ways in which mathematics . . .

Advocates for universal preschools win Grawemeyer Award . . .

Two medical school researchers win awards . . .

Lewis Walpole Library celebrates re-opening with exhibition

Peabody to honor Martin Luther King Jr.’s legacy with festival

Stanton Wheeler, was musician, master, sociologist and sports fan

Change of venue for Waith memorial

Campus Notes